Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Medical Treatment of Endometriosis-Associated Pelvic Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00229996
Recruitment Status : Completed
First Posted : September 30, 2005
Last Update Posted : January 24, 2014
Information provided by:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Brief Summary:
The Specific Aim of this project is to compare the efficacy and cost-effectiveness of continuous oral contraceptives versus leuprolide/norethindrone in the treatment of endometriosis-associated chronic pelvic pain. This comparison will be based on a randomized, double-blind, trial of women with chronic pelvic pain who have been diagnosed with endometriosis at the time of surgery within the last 3 years. We hypothesize that, over a 12-month period of postoperative treatment, the efficacy of oral contraceptives is no worse than leuprolide/norethindrone, and that treatment with oral contraceptives is more cost-effective.

Condition or disease Intervention/treatment Phase
Endometriosis Pelvic Pain Drug: Oral Contraceptive Drug: Depot-Leuprolide/Norethindrone Phase 3

Detailed Description:
  • Background-Laparoscopic surgical treatment for endometriosis is typically associated with a decrease of pain on a short-term basis, but 50% of patients have pain 12 months after surgery. Often this leads to having repeat surgery to treat the endometriosis. Instead of having repeat surgery, some physicians use medications to prevent the pain and endometriosis from returning.
  • The purpose of this study is to compare continuous oral contraceptives to depot-leuprolide for control of endometriosis-associated pelvic pain after surgical treatment of endometriosis. We will also be looking at the potential cost savings of using oral contraceptives compared to depot-leuprolide, as depot-leuprolide is an expensive medication.
  • If the patient meets criteria, including confirmation of diagnosis of endometriosis, she will then undergo an intake visit consisting of obtaining informed consent and completion of several baseline questionnaires. This intake visit is estimated to last 1-2 hours. After informed consent has been obtained, the subject will be randomized to one of the two treatment groups:One tablet of oral contraceptives (birth control pills) everyday and an injection of saline (a sterile salt solution with no medication effect) every 12 weeks for 48 weeks or One tablet of norethindrone everyday and an injection of depot-leuprolide every 12 weeks for 48 weeks.
  • The patient will be seen one month after the first injection (Visit 1) and then at 12 (Visit 2), 24 (Visit 3), 36 (Visit 4) and 48 (Visit 5) weeks. Blood pressure and weight will be recorded and a urine pregnancy test will be obtained. The Study Coordinator will review with the patient any concerns she might have and record any adverse events. Assessments of pain and quality of life will be made at weeks 4, 12, 24, 36 and 48 after the intake visit. An injection (leuprolide acetate or saline plus inert powder) will be given by an unblinded nurse at the intake visit, and at weeks 12, 24, and 36. In addition, at the end of each medication visit, the patient will be given a three month's supply of oral medication (capsules containing norethindrone acetate or a generic oral contraceptive with 30ug ethinyl estradiol and 0.15mg levonorgestrel).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 194 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Oral Contraceptives Versus Depot-Leuprolide Taken After Surgery for Endometriosis-Associated Pelvic Pain
Study Start Date : July 2004

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. pain
  2. quality of life

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 52 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age greater than 18 and pre-menopausal.
  • Pelvic pain of at least 3 months duration.
  • Diagnosis of endometriosis by laparoscopy or laparotomy within three years of entry. The diagnosis of endometriosis will require either histology consistent with endometriosis or operative records indicating visual evidence of lesions consistent with endometriosis.
  • Moderate to severe pelvic pain preoperatively attributable to endometriosis (average Numerical Rating Scale of 5 or more for three or more months).
  • Willingness to comply with visit schedule and protocol.

Exclusion Criteria:

  • Use of oral contraceptives within one month of the surgery.
  • Dose of Lupron within three months if given monthly or within five months if given 3-month injection.
  • Any disorder that represents a contraindication to the use of oral contraceptives (e.g. insulin-dependent diabetes mellitus, history of thrombophlebitis, hypertension, history of cardiovascular disease, smoker at 35 or more years of age) or GnRH analogs (e.g., history of osteopenia).
  • History of hysterectomy and bilateral salpingoophorectomy.
  • Positive pregnancy test at first postoperative (i.e, intake visit).
  • Significant mental or chronic systemic illness that might confound pain assessment or the inability to complete the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00229996

Layout table for location information
United States, Massachusetts
Brigham and Womens Hospital
Boston, Massachusetts, United States, 02215
Sponsors and Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Layout table for investigator information
Principal Investigator: David S Guzick, M.D., Ph.D University of Rochester
Principal Investigator: Mark Hornstein, MD Brigham and Women's Hospital
Principal Investigator: Fred M Howard, MD University of Rochester
Principal Investigator: Sara Sukalich, MD University of Rochester
Layout table for additonal information Identifier: NCT00229996    
Other Study ID Numbers: R01HD044870 ( U.S. NIH Grant/Contract )
First Posted: September 30, 2005    Key Record Dates
Last Update Posted: January 24, 2014
Last Verified: January 2014
Keywords provided by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD):
pelvic pain
Additional relevant MeSH terms:
Layout table for MeSH terms
Pelvic Pain
Neurologic Manifestations
Contraceptive Agents
Norethindrone Acetate
Contraceptives, Oral
Reproductive Control Agents
Physiological Effects of Drugs
Fertility Agents, Female
Fertility Agents
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Contraceptive Agents, Female
Contraceptives, Oral, Hormonal
Contraceptive Agents, Hormonal
Contraceptives, Oral, Synthetic